Desensitization of an adult patient with Pompe disease and a history of anaphylaxis to alglucosidase alfa

被引:23
|
作者
Lipinski, Shawn E. [1 ]
Lipinski, Michael J. [2 ]
Burnette, Autumn [3 ]
Platts-Mills, Thomas A. [3 ]
Wilson, William G. [1 ]
机构
[1] Univ Virginia Hlth Syst, Dept Pediat, Div Med Genet, Charlottesville, VA 22908 USA
[2] Univ Virginia Hlth Syst, Dept Internal Med, Charlottesville, VA 22908 USA
[3] Univ Virginia Hlth Syst, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA
关键词
Pompe disease; Enzyme replacement therapy; Lysosomal storage disease; Anaphylaxis; Allergy;
D O I
10.1016/j.ymgme.2009.07.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We report on the successful desensitization of an adult female with Pompe disease who had previously experienced anaphylaxis to intravenous alglucosidase alfa therapy. The starting alglucosidase alfa dose for desensitization was 10 mg/kg with gradual dose escalation and desensitization via serial dilution was completed over five infusions. This methodology serves as a means to desensitize patients with prior anaphylactic response to alglucosidase alfa so that enzyme replacement therapy can be utilized. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:319 / 321
页数:3
相关论文
共 50 条
  • [21] Efficacy of transitioning from alglucosidase alfa to avalglucosidase alfa in infantile-onset Pompe disease: A single-center cohort analysis
    Chien, Yin-Hsuan
    Chen, Hui-An
    Hsu, Rai-Hseng
    Yeh, Chien-Hua
    Fang, Ching-Ya
    Lee, Ni-Chung
    Hwu, Wuh-Liang
    Chien, Yin-Hsiu
    GENETICS IN MEDICINE, 2025, 27 (05)
  • [22] Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease
    Tim A Kanters
    Iris Hoogenboom-Plug
    Maureen PMH Rutten-Van Mölken
    W Ken Redekop
    Ans T van der Ploeg
    Leona Hakkaart
    Orphanet Journal of Rare Diseases, 9
  • [23] 36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy
    Regnery, Caroline
    Kornblum, Cornelia
    Hanisch, Frank
    Vielhaber, Stefan
    Strigl-Pill, Nicola
    Grunert, Birgit
    Mueller-Felber, Wolfgang
    Glocker, Franz Xaver
    Spranger, Matthias
    Deschauer, Marcus
    Mengel, Eugen
    Schoser, Benedikt
    JOURNAL OF INHERITED METABOLIC DISEASE, 2012, 35 (05) : 837 - 845
  • [24] Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease
    Nicolino, Marc
    Byrne, Barrv
    Wraith, J. Edmund
    Leslie, Nancy
    Mandel, Hanna
    Freyer, David R.
    Arnold, Georgianne L.
    Pivnick, Eniko K.
    Ottinger, C. J.
    Robinson, Peter H.
    Loo, John-Charles A.
    Smitka, Martin
    Jardine, Philip
    Tato, Luciano
    Chabrol, Brigitte
    McCandless, Shawn
    Kimura, Shigenzi
    Mehta, L.
    Bali, Deeksha
    Skrinar, Alison
    Morgan, Claire
    Rangachari, Lakshmi
    Corzo, Deya
    Kishnani, Priya S.
    GENETICS IN MEDICINE, 2009, 11 (03) : 210 - 222
  • [25] Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease
    Kanters, Tim A.
    Hoogenboom-Plug, Iris
    Rutten-Van Molken, Maureen P. M. H.
    Redekop, W. Ken
    van der Ploeg, Ans T.
    Hakkaart, Leona
    ORPHANET JOURNAL OF RARE DISEASES, 2014, 9
  • [26] Higher dose alglucosidase alfa is associated with improved overall survival in infantile-onset Pompe disease (IOPD): data from the Pompe Registry
    Kishnani, Priya S.
    Kronn, David
    Suwazono, Shugo
    Broomfield, Alexander
    Llerena, Juan
    Al-Hassnan, Zuhair Nasser
    Batista, Julie L.
    Wilson, Kathryn M.
    Periquet, Magali
    Daba, Nadia
    Hahn, Andreas
    Chien, Yin-Hsiu
    ORPHANET JOURNAL OF RARE DISEASES, 2023, 18 (01)
  • [27] Higher dose alglucosidase alfa is associated with improved overall survival in infantile-onset Pompe disease (IOPD): data from the Pompe Registry
    Priya S. Kishnani
    David Kronn
    Shugo Suwazono
    Alexander Broomfield
    Juan Llerena
    Zuhair Nasser Al-Hassnan
    Julie L. Batista
    Kathryn M. Wilson
    Magali Periquet
    Nadia Daba
    Andreas Hahn
    Yin-Hsiu Chien
    Orphanet Journal of Rare Diseases, 18
  • [28] Early Treatment With Alglucosidase Alfa Prolongs Long-Term Survival of Infants With Pompe Disease
    Kishnani, Priya S.
    Corzo, Deya
    Leslie, Nancy D.
    Gruskin, Daniel
    van der Ploeg, Ans
    Clancy, John P.
    Parini, Rosella
    Morin, Gilles
    Beck, Michael
    Bauer, Mislen S.
    Jokic, Mikael
    Tsai, Chen-En
    Tsa, Brian W. H.
    Morgan, Claire
    O'Meara, Tara
    Richards, Susan
    Tsao, Elisa C.
    Mandel, Hanna
    PEDIATRIC RESEARCH, 2009, 66 (03) : 329 - 335
  • [29] Effect of enzyme replacement therapy with alglucosidase alfa (Myozyme®) in 12 patients with advanced late-onset Pompe disease
    Papadopoulos, Constantinos
    Orlikowsld, David
    Prigent, Helene
    Lacour, Arnaud
    Tard, Celine
    Furby, Alain
    Praline, Julien
    Sole, Guilhem
    Hogrel, Jean-Yves
    De Antonio, Marie
    Semplicini, Claudio
    Deibener-Kaminsky, Joelle
    Kaminsky, Pierre
    Eymard, Bruno
    Taouagh, Nadjib
    Perniconi, Barbara
    Hamroun, Dalil
    Laforet, Pascal
    Bassez, G.
    Bedat-Millet, A. -L.
    Behin, A.
    Eymard, B.
    Leonard -Louis, S.
    Stojkovic, T.
    Canal, A.
    Decostre, V.
    Bouhour, F.
    Boyer, F.
    Caillaud, C.
    Castaing, Y.
    Chapon, F.
    Cintas, P.
    Durieu, I.
    Echaniz-Laguna, A.
    Feasson, L.
    Ferrer, X.
    Froissart, R.
    Piraud, M.
    Germain, D.
    Benistan, K.
    Guffon-Fouilhoux, N.
    Journel, H.
    Labauge, P.
    Levy, A.
    Magot, A.
    Pereon, Y.
    Minot-Myhie, M-C
    Nadaj-Pakleza, A.
    Nathier, C.
    Pellegrini, N.
    MOLECULAR GENETICS AND METABOLISM, 2017, 122 (1-2) : 80 - 85
  • [30] Early higher dosage of alglucosidase alpha in classic Pompe disease
    Spada, Marco
    Pagliardini, Veronica
    Ricci, Federica
    Biamino, Elisa
    Mongini, Tiziana
    Porta, Francesco
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2018, 31 (12) : 1343 - 1347